RNS Announcements

Final Results

28 June 2024

Notice of AGM

ProBiotix Health plc (AQSE: PBX), a life sciences business developing probiotics to tackle cardiovascular disease and other lifestyle conditions, announces its audited results for the period ended 31 December 2023. 


To view a full version of the results in 
PDF format  click here


  • Distribution agreement with Trans Chem for finished turnkey products in Australia and New Zealand
  • Appointment of Niels Peter Bak as Technical Product Manager
  • Launch of CholbiomeCH a dual action bilayer tablet containing phytosterols and LPLDL® to increase opportunities in the US market

Post period end

  • Appiontment of Michael Litichevski as Head of Global Sales
  • Appointment of Mads Brandt as Global Supply Chain Director
  • Partner agreement with SymbioPharm

Investor presentation

The Company will host a presentation for investors via the Investor Meet Company platform on Wednesday, 10 July at 11am BST. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9 July 2024 at 9am BST, or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet ProBiotix Health plc  via: https://www.investormeetcompany.com/probiotix-health-plc/register-investor

Investors who already follow ProBiotix Health plc on the Investor Meet Company platform will automatically be invited.

Steen Andersen, CEO of ProBiotix, commented: “We have continued to develop a business on becoming a solutions provider of finished probiotic products in consumer formats, both under our own brands and partner private labels, with the objective of building ProBiotix into a £10m turnover company in the years ahead.  We look to the future with enthusiasm and high confidence in building a valuable company for shareholders.”


For further information, please contact:

ProBiotix Health plc https://probiotixhealth-ir.com/
Steen Andersen, Chief Executive Contact via Walbrook below
Peterhouse Capital Ltd (Aquis Corporate Adviser and Broker) Tel: 020 7220 9797
Mark Anwyl Tel: 020 7469 0930
Duncan Vasey
Brefo Gyasi
Walbrook PR Ltd [email protected]
Anna Dunphy Mob: 07876 741 001